Collectively, these studies indicate that HER2, Nectin-4, and Trop-2, as key driver targets in bladder cancer, have seen their targeted therapeutics successfully transition from laboratory research to clinical application. The gene discussed is ERBB2; the disease is urinary bladder carcinoma.